EDIT vs TYL · rev $32.3M vs P/E 89, rev $2.14B
Editas Medicine Inc (EDIT) versus Tyler Technologies Inc (TYL) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Tyler Technologies Inc (TYL) is a software - application company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TYL revenue for 2024-12-31 was $2.14B. Net income was $263.0M. Revenue was up 9.5% from 2023-12-31 to 2024-12-31. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
EDIT currently screens at market cap $375.2M. TYL currently screens at market cap $25.57B and trailing P/E 89.3.
Not investment advice. Open the EDIT and TYL stock pages for the full models.
Not investment advice.